Strides Pharma Science Ltd
Strides Pharma Science Ltd is in the business of development and manufacturing of pharmaceutical products.[1] The company's pharmaceutical products are sold in over 100 countries.[2]
The company has always followed an inorganic growth strategy over the years that resulted in foray into new markets, addition of new business segments, therapy segments and manufacturing infrastructure.[3]
- Market Cap ₹ 8,370 Cr.
- Current Price ₹ 908
- High / Low ₹ 956 / 465
- Stock P/E 2.38
- Book Value ₹ 277
- Dividend Yield 0.44 %
- ROCE 14.7 %
- ROE 151 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company has delivered good profit growth of 128% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 50.4%
Cons
- Stock is trading at 3.28 times its book value
- The company has delivered a poor sales growth of 10.6% over past five years.
- Promoter holding is low: 28.3%
- Promoters have pledged or encumbered 50.1% of their holding.
- Earnings include an other income of Rs.3,313 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 15m | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1,341 | 1,196 | 2,861 | 2,755 | 2,845 | 2,178 | 2,752 | 3,316 | 3,070 | 3,688 | 3,890 | 4,565 | |
1,567 | 967 | 2,486 | 2,228 | 2,448 | 1,982 | 2,338 | 2,779 | 3,201 | 3,544 | 3,362 | 3,763 | |
Operating Profit | -226 | 229 | 374 | 527 | 398 | 197 | 414 | 537 | -131 | 145 | 528 | 803 |
OPM % | -17% | 19% | 13% | 19% | 14% | 9% | 15% | 16% | -4% | 4% | 14% | 18% |
3,281 | 874 | 63 | 291 | 643 | 303 | -43 | 109 | -112 | 92 | -100 | 3,313 | |
Interest | 109 | 47 | 168 | 183 | 196 | 79 | 156 | 150 | 177 | 261 | 280 | 249 |
Depreciation | 56 | 64 | 131 | 126 | 154 | 117 | 174 | 206 | 233 | 243 | 214 | 192 |
Profit before tax | 2,890 | 992 | 137 | 509 | 690 | 303 | 42 | 289 | -653 | -268 | -65 | 3,675 |
Tax % | 39% | 15% | 31% | 12% | 1% | -9% | 27% | 11% | -27% | -21% | 45% | 2% |
1,767 | 844 | 95 | 446 | 684 | 330 | 31 | 258 | -474 | -212 | -94 | 3,598 | |
EPS in Rs | 296.43 | 141.78 | 12.15 | 44.71 | 74.25 | 36.27 | 4.06 | 29.93 | -51.25 | -22.44 | -7.68 | 389.75 |
Dividend Payout % | 170% | 76% | 41% | 10% | 3% | 8% | 345% | 8% | 0% | -7% | -33% | 1% |
Compounded Sales Growth | |
---|---|
10 Years: | 14% |
5 Years: | 11% |
3 Years: | 14% |
TTM: | 17% |
Compounded Profit Growth | |
---|---|
10 Years: | 15% |
5 Years: | 128% |
3 Years: | 157% |
TTM: | 3668% |
Stock Price CAGR | |
---|---|
10 Years: | 4% |
5 Years: | 36% |
3 Years: | 80% |
1 Year: | 90% |
Return on Equity | |
---|---|
10 Years: | 21% |
5 Years: | 28% |
3 Years: | 50% |
Last Year: | 151% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 60 | 60 | 89 | 89 | 90 | 90 | 90 | 90 | 90 | 90 | 92 | 92 |
Reserves | 947 | 1,085 | 2,569 | 2,659 | 2,374 | 2,559 | 2,438 | 2,687 | 2,269 | 2,122 | 2,034 | 2,460 |
547 | 892 | 3,542 | 3,700 | 2,520 | 3,221 | 2,235 | 2,348 | 3,025 | 3,030 | 2,517 | 1,880 | |
543 | 438 | 1,211 | 1,598 | 1,601 | 1,937 | 1,369 | 1,844 | 1,556 | 1,352 | 1,157 | 1,498 | |
Total Liabilities | 2,096 | 2,475 | 7,410 | 8,046 | 6,585 | 7,807 | 6,131 | 6,969 | 6,940 | 6,594 | 5,799 | 5,929 |
555 | 701 | 2,679 | 2,980 | 2,977 | 3,648 | 2,099 | 2,219 | 2,347 | 2,311 | 1,865 | 1,899 | |
CWIP | 99 | 171 | 815 | 780 | 620 | 453 | 413 | 447 | 291 | 151 | 162 | 207 |
Investments | 443 | 630 | 1,341 | 1,525 | 588 | 702 | 549 | 697 | 540 | 490 | 303 | 409 |
999 | 972 | 2,576 | 2,762 | 2,400 | 3,005 | 3,070 | 3,605 | 3,762 | 3,642 | 3,470 | 3,414 | |
Total Assets | 2,096 | 2,475 | 7,410 | 8,046 | 6,585 | 7,807 | 6,131 | 6,969 | 6,940 | 6,594 | 5,799 | 5,929 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-272 | 83 | 73 | 288 | 187 | 60 | 205 | 481 | -258 | 44 | 701 | 684 | |
4,044 | 50 | -2,205 | -1,222 | 570 | -145 | 1,321 | -522 | -119 | 302 | -150 | -90 | |
-3,319 | -421 | 2,944 | 338 | -1,016 | 194 | -1,709 | -16 | 421 | -214 | -693 | -643 | |
Net Cash Flow | 454 | -288 | 812 | -596 | -259 | 110 | -184 | -56 | 45 | 133 | -142 | -48 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 99 | 119 | 132 | 132 | 113 | 165 | 124 | 122 | 144 | 129 | 107 | 96 |
Inventory Days | 90 | 135 | 149 | 209 | 146 | 294 | 254 | 329 | 285 | 257 | 235 | 236 |
Days Payable | 137 | 153 | 188 | 221 | 188 | 299 | 259 | 323 | 260 | 220 | 178 | 190 |
Cash Conversion Cycle | 52 | 102 | 92 | 120 | 71 | 160 | 119 | 128 | 168 | 165 | 164 | 141 |
Working Capital Days | 53 | -29 | 96 | 63 | 117 | 155 | 95 | 94 | 210 | 156 | 147 | 125 |
ROCE % | 113% | 57% | 8% | 11% | 16% | 2% | 5% | 8% | -5% | -0% | 7% | 15% |
Documents
Announcements
-
Reminder To Shareholders About Transfer Of Equity Shares Relating To Unclaimed Dividend Of The Company To Investor Education And Protection Fund ('IEPF')
9h - Reminder to shareholders to claim FY 2017-18 dividends before Oct 30, 2025, or shares transfer to IEPF.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
23 Jul - Earnings Call to discuss unaudited financial results of the Company for the quarter ended June 30, 2025.
-
Board Meeting Intimation for Intimation Regarding Board Meeting Under Regulation 29 Of SEBI (LODR) Regulations, 2015
23 Jul - Board meeting on July 29 to approve Q1 June 30, 2025 unaudited financial results.
-
Announcement under Regulation 30 (LODR)-Change in Management
22 Jul - Strides announces senior management changes and explains delay in disclosure compliance.
-
Business Responsibility and Sustainability Reporting (BRSR)
11 Jul - Strides Pharma submits FY25 Business Responsibility & Sustainability Report detailing ESG and governance disclosures.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
Concalls
-
May 2025Transcript PPT
-
Feb 2025Transcript PPT REC
-
Oct 2024TranscriptPPT
-
Oct 2024Transcript PPT
-
Aug 2024TranscriptPPT
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT REC
-
Nov 2023Transcript PPT
-
Oct 2023TranscriptPPT
-
Aug 2023TranscriptPPT
-
Jun 2023Transcript PPT
-
Feb 2023TranscriptPPT
-
Nov 2022TranscriptPPT
-
Aug 2022TranscriptPPT
-
Jun 2022Transcript PPT
-
Feb 2022TranscriptPPT
-
Nov 2021TranscriptPPT
-
Aug 2021TranscriptPPT
-
May 2021TranscriptPPT
-
Feb 2021TranscriptPPT
-
Oct 2020TranscriptPPT
-
Aug 2020TranscriptPPT
-
May 2020TranscriptPPT
-
Jan 2020TranscriptPPT
-
Dec 2019TranscriptPPT
-
Jul 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Jan 2019TranscriptPPT
-
Aug 2018TranscriptPPT
-
May 2018TranscriptPPT
-
Feb 2018TranscriptPPT
-
Oct 2017TranscriptPPT
-
Aug 2017TranscriptPPT
-
May 2017TranscriptPPT
-
Feb 2017TranscriptPPT
-
Oct 2016TranscriptPPT
-
Aug 2016TranscriptPPT
-
May 2016TranscriptPPT
-
Feb 2016TranscriptPPT
Business Segments
1) Pharma Generics: Its generic pharma business is driven by IP-based product licensing and global marketing and distribution partnerships. It specializes in manufacturing niche generic formulations in various dosage forms, like tablets, capsules, liquids, and sachets, focusing on regulated markets including the United States, Europe, Australia, etc. It has emerged as one of the world’s leading producers of soft gelatin capsules. [1] [2]